Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment of prevention of toll-like receptor-4-associated disorders

• US 8,518,905 B2
• Filed: 05/01/2012
• Issued: 08/27/2013
• Est. Priority Date: 04/19/2007
• Status: Active Grant

• Current Assignee: University of Pittsburgh of The Commonwealth System of Higher Education
• Original Assignee: University of Pittsburgh of The Commonwealth System of Higher Education
• Inventors: Hackam, David J., Gribar, Steven C.
• Primary Examiner(s): McGarry, Sean
• Application Number:
  US13/461,672
• Publication Number:
  US 20130072547A1
• Time in Patent Office: 483 Days
• Field of Search: None
• US Class Current: 514/44.R
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/06 Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical

Abstract

The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.

Claims

1. A method of reducing the risk of an infant developing necrotizing enterocolitis comprising administering, to the infant, an effective amount of a TLR9 agonist.

2. The method of claim 1, wherein the TLR9 agonist is an oligonucleotide comprising an unmethylated CpG dinucleotide.